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Abstract: Seaweeds are an underexploited and potentially sustainable crop which offer a rich source 
of bioactive compounds, including novel complex polysaccharides, polyphenols, fatty acids, and 
carotenoids. The purported efficacies of these phytochemicals have led to potential functional food 
and nutraceutical applications which aim to protect against cardiometabolic and inflammatory risk 
factors associated with non-communicable diseases, such as obesity, type 2 diabetes, metabolic 
syndrome, cardiovascular disease, inflammatory bowel disease, and some cancers. Concurrent 
understanding that perturbations of gut microbial composition and metabolic function manifest 
throughout health and disease has led to dietary strategies, such as prebiotics, which exploit the 
diet-host-microbe paradigm to modulate the gut microbiota, such that host health is maintained or 
improved. The prebiotic definition was recently updated to “a substrate that is selectively utilised 
by host microorganisms conferring a health benefit”, which, given that previous discussion 
regarding seaweed prebiotics has focused upon saccharolytic fermentation, an opportunity is 
presented to explore how non-complex polysaccharide components from seaweeds may be 
metabolised by host microbial populations to benefit host health. Thus, this review provides an 
innovative approach to consider how the gut microbiota may utilise seaweed phytochemicals, such 
as polyphenols, polyunsaturated fatty acids, and carotenoids, and provides an updated discussion 
regarding the catabolism of seaweed-derived complex polysaccharides with potential prebiotic 
activity. Additional in vitro screening studies and in vivo animal studies are needed to identify 
potential prebiotics from seaweeds, alongside untargeted metabolomics to decipher microbial-
derived metabolites from seaweeds. Furthermore, controlled human intervention studies with 
health-related end points to elucidate prebiotic efficacy are required. 
Keywords: seaweed; gut microbiota; prebiotics; dietary fibre; complex polysaccharides; 
polyphenols; polyunsaturated fatty acids; carotenoids; phytochemicals 
 
1. Introduction 
Seaweeds are an underexploited and sustainable crop which offer a rich source of bioactive 
compounds, including novel dietary fibres, polyphenols, fatty acids, and carotenoids [1,2]. 
Epidemiological evidence comparing Japanese and Western diets have correlated seaweed 
consumption (5.3 g/day in Japan) with decreased incidence of chronic disease [3], while the purported 
efficacies of seaweed phytochemicals have led to potential functional food and nutraceutical 
applications which aim to protect against cardiometabolic and inflammatory risk factors associated 
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with non-communicable diseases, such as obesity, type two diabetes, metabolic syndrome, 
cardiovascular disease, inflammatory bowel disease, and some cancers [1].  
Current understanding of mutualistic diet-host-microbe interactions has generated efforts to 
exploit diet to maintain health status, and to prevent or overcome non-communicable diseases, where 
an imbalance of gut microbiota composition and metabolic function manifests during the onset and 
pathophysiology of gastrointestinal, neurological, and cardio-metabolic diseases, often congruent 
with intestinal inflammation and compromised gut barrier function [4,5]. As such, it has become 
pertinent to explore dietary strategies which modulate gut microbial composition and function to 
improve host health. This includes the use of prebiotics as fermentable substrates to enable selective 
gut commensal metabolism.  
The prebiotic definition was recently updated to “a substrate that is selectively utilised by host 
microorganisms conferring a health benefit” [6], which includes the inhibition of pathogens, immune 
system activation, and vitamin synthesis and provides opportunity to explore the prebiotic efficacy 
of non-complex polysaccharide components such polyphenols, phytochemicals, and 
polyunsaturated fatty acids (PUFAs) [6]. It is also recognised that other microbial species have the 
potential to catabolise prebiotics, besides the classical examples of Bifidobacterium and Lactobacillus 
[6], courtesy of culture-independent techniques, such as 16S rRNA next generation sequencing and 
whole genome shotgun metagenomic sequencing which have provided taxonomic classification to 
identify microbial abundance/diversity and inferred or identified metabolic function [7]. 
Given that previous discussion regarding the prebiotic potential of seaweed components has 
focused solely upon the saccharolytic fermentation of complex polysaccharides and the physiological 
effects of short chain fatty acid metabolites (SCFAs) [3,8,9], scope exists to explore the prebiotic 
potential of other phytochemical components derived from seaweeds, namely polyphenols, 
carotenoids, and PUFAs, applicable to both human and animal health.  
This review aims to provide an updated discussion regarding the fermentation and potential 
prebiotic effect of seaweed polysaccharides and oligosaccharides, based on recent evidence from in 
vitro fermentation studies and in vivo animal models, and to postulate how other seaweed 
phytochemicals, such as polyphenols, PUFAs, and carotenoids, may interact with the gut microbiota 
to manipulate microbial composition and/or function to elicit bioactivities pertained to a prebiotic. 
The latter provides new opportunities to complete prebiotic screening studies using in vitro 
techniques and pre-clinical animal models to understand how parent compound biotransformation 
into endogenously-derived or gut microbiota-derived metabolites impact bioaccessibility and 
bioavailability to influence gut microbial community structure and function, conducive to a prebiotic 
effect. Evidence from clinical trials with health-related end-points and mechanistic insight is 
imperative to substantiate health claims associated with a prebiotic effect. 
2. Complex Polysaccharides 
Seaweeds contain 2.97–71.4% complex polysaccharides [2,3], which include alginate, fucoidan, 
and laminarin in brown seaweeds; xylan and sulphated galactans, such as agar, carrageenan, and 
porphyran in red seaweeds; whilst ulvan and xylan are found in green seaweeds. The 
monosaccharide composition of the major brown, red, and green seaweed glycans are presented in  
Table 1 Table 2 Table 3, respectively. Whilst no human study to date has explored prebiotic sources 
from seaweeds, several in vitro studies [10–13], and in vivo animal studies [14,15], have explored the 
prebiotic potential seaweeds and their polysaccharide components. 
Seaweed polysaccharides are atypical in structure to terrestrial glycans, and are understood to 
resist gastric acidity, host digestive enzymes, and gastrointestinal absorption [8]. Seaweed glycans 
may, therefore, serve as fermentation substrates for specific gut microbial populations or facilitate 
substrate cross-feeding of partially broken-down intermediates, such as oligosaccharides and 
metabolic cross-feeding of SCFAs to cause indirect proliferation of specific bacteria [16–20]. The 
physiological effects of SCFAs, primarily acetate, propionate, and butyrate, include the reduction of 
luminal pH to inhibit pathogens, the provision of energy sources to colonocytes, and the activation 
of free fatty acid receptors; where acetate and propionate are ligands for anorexigenic pathways in 
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appetite regulation and can inhibit the rate limiting step of hepatic cholesterol synthesis via 3-
hydroxy-3-methylglutaryl CoA reductase inhibition [21–23]. 
To facilitate saccharolytic fermentation in the colon, the gut microbiota must express functional 
carbohydrate active enzymes (CAZymes) to catabolise seaweed glycans as carbon sources within the 
colonic digesta. The repertoire of CAZymes expressed by the human gut microbiota includes 
glycoside hydrolase and polysaccharide lyase families to facilitate degradation via hydrolysis and 
elimination reactions, respectively [24–26]. Whole genome sequencing has previously identified gene 
clusters which encode the catabolic machinery responsible for the breakdown of prebiotics, which 
includes the CAZyme families responsible for the catabolism of inulin, lactulose, fructo-
oligosaccharides, xylo-oligosaccharides, and galacto-oligosaccharides by human gut commensal 
strains, including Bifidobacterium longum NCC2705, Bifidobacterium adolescentis ATCC 15703, 
Streptococcus thermophilus LMD9, Eubacterium rectale ATCC 33656, Bacteroides vulgatus ATCC 8482, 
and Fecalibacterium prausnitzii KLE1255 [27]. 
Based on open source data from the Carbohydrate-Active enZYmes Database [28], Tables 1–3 
detail the CAZyme families which may exert specificity for seaweed glycans and highlights the gut 
bacterial populations which have demonstrable evidence for seaweed glycan utilisation. This is 
dominated by Bacteroides, which have extensive glycolytic versatility [26,29]. This may explain why 
in vitro batch culture fermentation data of seaweeds and seaweed glycans indicate the proliferation 
of Bacteroides; whilst the degradation of complex seaweed glycans by Bacteroides could also facilitate 
the cross-feeding of oligosaccharides, monosaccharides, and SCFAs for gut commensals deemed 
beneficial to health, including Bifidobacterium. 
In vitro fermentation studies are frequently used as screening tools to model colonic 
fermentation and determine substrate utilisation by an ex vivo faecal inoculum, with seaweed as a 
sole carbon source. An overview of recent in vitro fermentation studies which have evaluated the 
fermentation of whole seaweeds or extracted complex polysaccharide components by the human gut 
microbiota is presented in Table 4 (brown seaweeds), Table 5 (red seaweeds), and Table 6 (green 
seaweeds). These tables include differences in study methodologies, for example, test substrate 
dosage; the use of an in vitro digestion before the fermentation experiment (declared within the 
methods section of the cited research paper); how the inoculum was prepared; duration of the faecal 
fermentation experiment; microbial enumeration method; and the analytical technique used to 
ascertain metabolite changes during the fermentation. The use of an in vitro digestion before in vitro 
fermentation is often used to determine whether a substrate is resistant to endogenous digestive 
enzymes and small intestinal absorption, and to provide the fraction of a dietary component which 
is bioaccessible in the colon [30]. The lack of an in vitro digestion before fermentation experiments 
may cause false positive results, given that low molecular weight components present in seaweed 
extracts, normally absorbed in the small intestine, are used as fermentation substrates for the ex vivo 
microbiota. Table 7 highlights data from in vivo rodent studies which have evaluated the potential 
prebiotic effect of seaweeds and seaweed glycans.  
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Table 1. Potential degradation of brown seaweed glycans by the human gut microbiota. 
Carbohydrate 
Carbohydrate-Active 
Enzyme (CAZyme) 
Evidenced Glycolytic 
Bacteria 
Reference 
Alginate 
1,4-β-D-mannuronic 
acid 
α-L-guluronic acid 
PL6 Alginate lyase 
PL6 MG-specific alginate 
lyase 
Bacteroides clarus 
Bacteroides eggerthii 
 
PL15 Alginate lyase 
PL15 Oligoalginate lyase 
Bacteroides ovatus 
Bacteroides 
thetaiotaomicron 
Bacteroides xylanisolvens 
[31–36] 
PL17 Alginate lyase 
PL17 Oligoalginate lyase 
Bacteroides clarus 
Bacteroides eggerthii 
 
Fucoidan 
Sulphated 1,2-1,3-1,4-
α-L-fucose 
GH29 α-L-fucosidase 
GH29 α-1,3/1,4-L-fucosidase 
Not determined [37] 
GH95 α-L-fucosidase 
GH95 α-1,2-L-fucosidase 
Laminarin 1,3-1,6-β-glucose 
GH16 β-glucanase 
GH16 β-1,3-1,4-glucanase 
GH16 endo-1,3-β-glucanase 
Bacteroides distasonis 
Bacteroides fragilis 
Bacteroides 
thetaiotaomicron 
[10,38] 
PL, Polysaccharide Lyase family; GH, Glycoside Hydrolase family. Potential glycolytic bacteria were 
identified using the Carbohydrate-Active enZYmes Database [28]. 
Table 2. Potential degradation of red seaweed glycans by the human gut microbiota. 
Carbohydrate 
Carbohydrate-Active 
Enzyme (CAZyme) 
Evidenced 
Glycolytic Bacteria 
Reference 
Agar (Galactan) 
1,3-β-D-galactose 
1,4-3,6-anhydro-α-
L-galactose 
GH2 β-galactosidase 
Bacteroidetes plebeius [39–42] 
GH16 β-agarase 
GH86 β-agarase 
GH117 1,3-α-3,6-anhydro-L-
galactosidase 
Carrageenan 
(Galactan) 
1,4-β-D-galactose 
1,3-α-D-galactose 
3,6-anhydro-D-
galactose 
GH2 β-galactosidase 
Bacteroides plebeius [41,43] GH117 1,3-α-3,6-anhydro-L-
galactosidase 
Porphyran 
(Galactan) 
Sulphated 1,3-β-D-
galactose 
1,4-α-L-galactose-6-
sulfate 
3,6-anhydro-α-L-
galactose 
GH16 β-porphyranase 
GH86 β-porphyranase 
Bacteroides plebeius [41,44,45] 
Xylan 1,3-1,4-β-D-xylose GH3 xylan 1,4-β-xylosidase Not determined [46–49] 
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GH5 endo-1,4-β-xylanase 
GH10 endo-1,4-β-xylanase 
GH10 endo-1,3-β-xylanase 
GH11 endo-β-1,4-xylanase 
GH11 endo-β-1,3-xylanase 
GH43 β-xylosidase 
GH43 xylanase 
GH43 β-1,3-xylosidase 
GH67 xylan α-1,2-
glucuronidase 
GH115 xylan α-1,2-
glucuronidase 
CE1−CE7 and CE12 acetyl 
xylanesterases 
PL, Polysaccharide Lyase family; GH, Glycoside Hydrolase family. Potential glycolytic bacteria were 
identified using the Carbohydrate-Active enZYmes Database [28]. 
Table 3. Potential degradation of green seaweed glycans by the human gut microbiota. 
Carbohydrate 
Carbohydrate-Active Enzyme 
(CAZyme) 
Evidenced Glycolytic 
Bacteria 
Reference 
Ulvan 
Sulphated 1,4-β-D-
Glucuronic acid 
α-L-Rhamnose 
1,4-β-D-xyloglucan 
GH78 α-L-rhamnosidase 
Not determined [50,51] 
GH145 α-L-rhamnosidase 
Xylan 1,3-β-D-xylose 
GH10 endo-1,3-β-xylanase, 
Not determined [52] GH11 endo-β-1,3-xylanase 
GH43 β-1,3-xylosidase 
PL, Polysaccharide Lyase family; GH, Glycoside Hydrolase family. Potential glycolytic bacteria were 
identified using the Carbohydrate-Active enZYmes Database [28]. 
2.1. Brown Seaweed Polysaccharides 
Brown seaweeds are commonly used as food ingredients owing to their commercial abundance 
[53]. The anti-obesogenic effects of brown seaweeds are reported in mice, where supplementation of 
5% (w/w) Saccorhiza polyschides extract, containing 12% dietary fibre, reduced body weight gain and 
fat mass of mice with diet-induced obesity [54]. The anti-obesogenic effect was attributed to the 
fermentation of alginate and fucoidan complex polysaccharide components, owing to reduced 
microbial bile salt hydrolase activity; however, no gut microbial compositional data were provided. 
Elsewhere, the in vitro evidence (Table 4) indicates that whole brown seaweeds and their extracted 
complex polysaccharide components are fermented by the ex vivo faecal microbiota, with increased 
production of acetate, propionate, butyrate, and total SCFAs reported during fermentation 
experiments. A corresponding increase in populations, such as Bifidobacterium, Bacteroides, 
Lactobacillus, Roseburia, Parasutterella, Fusicatenibacter, Coprococcus, Fecalibacterium is also reported [55–
57].  
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2.1.1. Alginate 
Alginates are composed of 1,4-linked α-L-guluronic (G) and β-D-mannuronic acid (M) residues 
to form GM, GG and MM blocks, and represent 17−45% dry weight of brown seaweeds [58]. The 
colloidal properties of alginates have wide application in food processing, biotechnology, medicine 
and pharmaceutical industries [59], while degraded sodium alginate is an approved item of “foods 
with specified uses”, under the categories of “Foods that act on cholesterol plus gastrointestinal 
conditions” and “Foods that act on blood cholesterol levels” in Japan [60]. The presence of water 
soluble alginate oligosaccharides in the faeces of pigs fed alginate is indicative of alginate lyase 
activity by the luminal or mucus adherent gut microbiota [61], although an adaptation period of > 39 
days is reported for the degradation of G blocks by the porcine microbiota whilst M blocks are readily 
degraded [62]. 
The capacity for alginate to modulate the gut microbiota of Japanese individuals was highlighted 
over 20 years ago [63], where alginate supplementation (30 kDa, 10 g/day, n = 8) significantly 
increased faecal Bifidobacterium populations in healthy male volunteers after both one and two weeks, 
alongside significantly increased acetic and propionic acids after two weeks. Deleterious metabolites, 
including faecal sulphide, phenol, p-cresol, indole, ammonia and skatole were significantly reduced 
compared to the control (free living) diet. Notably, faecal Bifidobacterium counts and SCFA 
concentrations returned to baseline in the week after alginate diet cessation, which highlights the 
transient nature of the gut microbiota and the need for greater powered long-term human 
intervention studies. 
Subsequent in vitro fermentation studies have indicated that alginate is fermented by the human 
gut microbiota, for example, a 24 h in vitro fermentation of a 212 kDa alginate increased total bacterial 
populations, although no statistical increase in individual Bifidobacterium, Bacteroides/Prevotella, 
Lactobacillus/Enterococcus, Eubacterium rectale/Clostridium coccoides, or Clostridium histolyticum 
populations were observed [11]. Acetic acid, propionic acid and total SCFAs were significantly 
increased after 24 h fermentation with the 212 kDa alginate, while alginate of 97 kDa increased total 
SCFA and acetate production after 10 h of fermentation. Alginates of 38 kDa, and 97 kDa did not 
change microbial abundance, although the authors could not correlate molecular weight with 
fermentation patterns. 
Alginate oligosaccharides (AOS) (~3.5 kDa) can be obtained via acidic or enzymatic hydrolysis 
of alginate polysaccharides [58], and enzymatically derived AOS has promoted the growth of 
Bifidobacterium bifidum ATCC 29521, Bifidobacterium longum SMU 27001 and Lactobacilli, in vitro 
[64,65]. Supplementation of 2.5% AOS for two weeks significantly increased faecal Bifidobacterium. in 
rats compared to control and 5% FOS supplemented diets (13-fold and 4.7-fold increase, respectively), 
while faecal Lactobacillus were 5-fold greater in rats who consumed AOS compared to FOS. 
Enterobacteriaceae and Enterococcus populations were significantly decreased following AOS 
supplementation. Elsewhere, the hydrolysis of alginate, mannuronic acid oligosaccharides (MO) and 
guluronic oligosaccharides (GO) during a 48 h batch culture fermentation with the faecal microbiota 
of Chinese individuals demonstrated increased production of acetate, propionate, butyrate, and total 
SCFAs compared to the substrate-free control, where GO generated the greatest increase [36]. 
Subsequent strain isolation from the stools of individuals who demonstrated alginate degradation 
during fermentation identified Bacteroides xylanisovlens G25, Bacteroides thetaiotomicron A12, 
Bacteroides ovatus A9, and Bacteroides ovatus G19 as strains capable of hydrolysing alginate and AOS, 
where Bacteroides ovatus G19 expressed α-1,4-guluronanlyase and β-1,4-mannuronanlyase CAZymes 
[34].  
A Bacteroides xylanisolvens strain with 99% similarity to Bacteroides xylanisolvens XB1A was 
recently isolated from the stool of a Chinese individual and the alginate lyase gene expressed was 
100% homologous to the alginate lyase of Bacteroides ovatus strain ATCC 8483 [33]. The preceding in 
vitro fermentation study demonstrated increased production of acetate, propionate, butyrate, and 
total SCFAs compared to the soluble starch control vessel following a 72 h fermentation of alginate.  
Alginate lyase depolymerises alginate polysaccharides to lower molecular weight 
oligosaccharides via β-elimination, and is most commonly expressed by marine bacteria, including 
Mar. Drugs 2019, 17, 327 7 of 42 
 
Flammeovirga, Vibrio, Pseudoalteromonas, Glaciecola chathamensis S18K6, and Zobellia galactanivorans [65–
69], while the terrestrial bacteria Paenibacillus sp. Strain MY03 was recently reported to possess genes 
encoding alginate lyase and agarase enzymes [70]. The acquisition of genes encoding alginate lyase 
enzymes by human gut Bacteroides is a suggested consequence of horizontal gene transfer from the 
marine environment [31,71], where seaweed consumption may have provided a vector to exert a 
selective pressure to induce diet-driven adaptations of the gut microbiota [35,72–76]. Recent work by 
Matthieu et al. [35] suggests that an alginate degradation system within the genome of human gut 
Bacteroides was a result of ancient acquisition, where the polysaccharide utilisation loci encodes PL6 
and PL17 alginate lyase enzymes and hypothetical proteins responsible for alginate recognition, 
internalisation, and catabolism, including bacterial ABC transporter proteins to facilitate alginate 
uptake across the bacterial membrane [77]. Nevertheless, in vivo rodent studies have demonstrated 
that seaweed glycans are fermented even though animals have never been exposed to dietary 
seaweeds before the intervention, which suggests that the gut microbiome contains genes for 
CAZymes which can degrade seaweed glycans when expressed. 
2.1.2. Laminarin 
Laminarin is a water-soluble storage polysaccharide consisting of 1,3- or 1,6-β-glucose with an 
average molecular weight of 5 kDa [78] and accounts for 10–35% of the dry weight of brown seaweeds 
[58]. One in vitro batch culture fermentation of laminarin demonstrated increased Bifidobacteria and 
Bacteroides after 24 h [79], while another demonstrated increased propionate and butyrate production 
after 24 h [14]. A subsequent in vivo rat study (143 mg laminarin per kg body weight per day for 14 
days) indicated that laminarin was not selectively fermented by Lactobacillus and Bifidobacterium, but 
could modify jejunal, ileal, caecal and colonic mucus composition, secretion, and metabolism to 
protect against bacterial translocation. The authors suggest that increased luminal acidity and/or 
catabolism of laminarin by mucolytic commensals could elicit such effects, which corroborates the 
evidence that a complex polysaccharide-rich diet maintains mucus layer integrity to promote gut 
barrier function [80,81]. Future studies regarding intestinal mucus modulation by laminarin may 
wish to characterise gut microbiota compositional and functional changes following laminarin 
ingestion, to detect the abundance and metabolic activity of glycan degraders, such as Bacteroides 
[82,83] or mucolytic species associated with health, such as Akkermansia muciniphila or Ruminococcus 
[84,85]. Elsewhere, laminarin increased L-cell GLP-1 secretion to attenuate diet-induced obesity in 
mice, and improved glucose homeostasis and insulin sensitivity [86]. The authors suggested that the 
observed cytosolic Ca2+ cascade caused GLP-1 secretion, which is in agreement with GPR41/43 
receptor activation by SCFAs produced by gut microbial fermentation [87,88], however, data 
obtained to assess laminarin-induced changes to gut microbiota composition and metabolic output 
is needed to ascribe a prebiotic effect in this study.  
The abundance of glycoside hydrolase and β-glucosidase enzymes expressed by the human gut 
microbiota may have the capacity to catabolise laminarin [24,89–91], for example, a Bacteroides 
cellulosyliticus WH2 human gut isolate was able to grow on laminarin-supplemented minimal media 
in vitro, (incidentally it did not grow on alginate, carrageenan, or porphyran) [92]; however, the 
molecular mechanisms by which human gut Bacteroides breakdown laminarin are likely distinct from 
those responsible for the degradation of mix linked β 1,3- 1,4- glucans, such as those found in cereals 
(e.g., by BoGH16MLG) [93]. 
2.1.3. Fucoidan 
Fucoidans are water soluble polysaccharides composed of sulphated 1,2- or 1,3- or 1,4-α-L-fucose 
which exist as structural polysaccharides in brown seaweeds and occupy 5–20% of algal dry weight 
[58,94]. The structural heterogeneity of fucoidan encompasses varying degrees of branching, sulphate 
content, polydispersity, and irregular monomer patterns, which can include fucose, uronic acid, 
galactose, xylose, arabinose, mannose, and glucose residues [9,59,95].  
A recent in vitro fermentation study of fucoidan (<30 kDa) extracted from Laminaria japonica 
demonstrated a greater increase in Bifidobacterium  and Lactobacillus  following 24 h and 48 h 
Mar. Drugs 2019, 17, 327 8 of 42 
 
fermentation relative to >30 kDa fucoidan [12], while fucoidan from Ascophyllum nodosum (1330 kDa) 
and Laminaria japonica (310 kDa) were shown to increase Lactobacillus and Ruminococcaceae, 
respectively, in the caecal microbiota of mice gavaged with 100 mg/kg/day [96]. Fucoidan also 
reduced serum LPS-binding protein levels in this study—indicative of a reduced antigen load and reduced 
inflammatory response. In contrast, fucoidan with a fucose-rich and highly sulphated fucoidan 
extracted from Cladosiphon okamuranus was not fermented by the rat gut microbiota [97].  
While the purported bioactivities of fucoidan include anti-obesogenic, anti-diabetic, anti-
microbial, and anti-cancer properties [98], there is limited evidence to implicate a role for the gut 
microbiota with such bioactivities, and studies are needed to evaluate the structure-dependent 
fermentation of fucoidan to ascribe a prebiotic effect. For the latter, this is surprising given the myriad 
of α-fucosidase enzymes present in the human gut bacterial glycobiome. 
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Table 4. In vitro fermentation of brown seaweeds with human faecal inoculum. 
Seaweed Substrate Dose 
Use of a Simulated in vitro 
Digestion Before Fermentation? 
Experimental 
Parameters 
Microbial 
Enumeration 
Microbial Changes 
Metabolomics 
Analysis Technique 
Metabolite 
Changes 
Reference 
Ecklonia 
radiata 
Crude fraction (CF) 
Phlorotannin-enriched 
fraction (PF) 
Low-molecular weight 
polysaccharide fraction (LPF) 
High-molecular weight 
polysaccharide fraction (HPF) 
1.5% 
(w/v) 
Yes 
CF = 71.5% digestible 
PF = 87.3% digestible 
LPF = 86.1% digestible 
HPF = non-digestible 
10% (w/v) pooled 
inoculum 
(n = 3) 
24 h 
qPCR 
↑ Bifidobacterium ↑ 
Lactobacillus 
 (LPF) 
↑ F. prausnitzii ↑ C. coccoides  
↑ Firmicutes 
(CF, LPF) 
↑ Bacteroidetes ↑E. coli 
(CF, PF, LPF, HPF) 
↓ Enterococcus  
(CF, PF) 
GC-FID 
↑Acetate 
(CF) 
↑Propionate 
(CF, LPF, HPF) 
↑ Butyrate 
(CF, LPF, HPF) 
↑ Total SCFA 
(CF, LPF, HPF) 
[56]  
Ecklonia 
radiata 
Water extract (WE) 
Acid extract (AE) 
Celluclast enzyme extract 
(CEE) 
Alcalase enzyme extract 
(AEE) 
Free sugar fraction (FF) 
Polysaccharide fraction (PF) 
Seaweed residue (SR) 
Seaweed powder (SP) 
1.5% 
(w/v) 
No – digestibility unknown 
10% (w/v) pooled 
inoculum  
(n = 3) 
24 h 
qPCR 
= F. prausnitzii = C. leptum 
= R. bromii ↑ Total bacteria 
(CEE, AEE, WE, FF) 
↑ Bifidobacterium ↑ 
Bacteroidetes 
↑ Lactobacillus ↑ C. coccoides 
(CEE) 
↑ E. coli ↑ Enterocccus 
(WE, AE, CEE, AEE, FF, PF, 
SP) 
GC-FID 
↑ Acetate 
↑ Propionate 
↑ Butyrate 
(WE, AE, CEE, 
AEE, FF, PF, SP) 
↑ Total SCFA 
[57]  
qPCR, Quantitative PCR; GC-FID, Gas Chromatography with Flame Ionisation Detector; SCFA, Short Chain Fatty Acid; =, no statistical difference compared to the control; 
↑, significant increase compared to the control; ↓ significant decrease compared to the control. Microbial and metabolite changes with abbreviations in parenthesis indicate 
the substrate(s) which exerted the effect. If no abbreviations in parenthesis are presented, then all of the seaweed substrates tested exerted the effect. 
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Table 4. continued. 
Seaweed  Substrate Dose 
Use of a Simulated 
in vitro Digestion 
Before 
Fermentation? 
Experimental 
Parameters 
Microbial 
Enumeration 
Microbial Changes 
Metabolomics 
Analysis 
Technique 
Metabolite 
Changes 
Reference 
Sargassum 
muticum  
Sargassum muticum 
Alcalase enzyme 
extract (SAE) 
1% 
(w/v) 
Yes – non-digestible 
(% digestible 
undisclosed) 
10% (w/v) single 
inoculum 
24 h 
FISH 
= Bifidobacterium  
= Lactobacillus 
= Clostridium histolticum 
↑ Bacteroides/Prevotella  
↓ C.coccoides/E.rectale 
HPLC ↑ Total SCFA [99]  
Sargassum 
thunbergii 
Polysaccharide 
extract 
0.3% 
(w/v) 
No – digestibility 
unknown 
20% (w/v) pooled 
inoculum  
(n=3)  
24 h 
16S rRNA  
NGS 
↑ Bacteroidetes  
↑Bacteroidetes:Firmicutes 
ratio  
↑ Bifidobacterium  
↑ Roseburia  
↑ Parasutterella  
↑ Fusicatenibacter  
↑ Coprococcus  
↑ Fecalibacterium  
GC-MS 
↑ Acetate  
↑ Propionate  
↑ Butyrate  
↑ Valerate  
↑ Total SCFA 
[55]  
FISH, Flourescence in situ Hybridisation; 16S rRNA NGS, 16S rRNA Next Generation Sequencing; HPLC, High Performance Liquid Chromaography; GC-MS, Gas 
Chromatography-Mass Spectrometry; SCFA, Short Chain Fatty Acid; =, no statistical difference compared to the control; ↑, significant increase compared to the control; 
↓ significant decrease compared to the control. Microbial and metabolite changes with abbreviations in parenthesis indicate the substrate(s) which exerted the effect. If 
no abbreviations in parenthesis are presented, then all of the seaweed substrates tested exerted the effect. 
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Table 4. continued. 
Seaweed Substrate Dose 
Use of a Simulated 
in vitro Digestion 
Before 
Fermentation? 
Experimental 
Parameters 
Microbial 
Enumeration 
Microbial Changes 
Metabolomics 
Analysis 
Technique 
Metabolite 
Changes 
Reference 
- Alginate 5% (w/v) 
No – digestibility 
unknown 
10% (w/v) 
single 
inoculum 
72 h 
16S rRNA 
DGGE 
16S rRNA 
NGS 
↑ Bacteroides  GC-FID 
↑ Propionate 
↑ Butyrate 
↑ Total SCFA 
[33] 
- 
Alginate (A) 
Mannuronic acid 
oligosaccharides (MO) 
Guluronic acid 
oligosaccharides (GO) 
Propylene glycol alginate 
sodium sulphate (PSS) 
5g/L (A) 
8g/L 
(MO, 
GO, 
PSS) 
No – digestibility 
unknown 
10% (w/v) 
single 
inoculum 
48 h 
16S rRNA 
DGGE 
Detection of Bacteroides 
xylanisolvens, Clostridium 
clostridioforme/Clostridium 
symbiosum, Bacteroides 
finegoldii, Shigella 
flexneri/E.coli, E.fergusonii, 
and Bacteroides ovatus 
HPLC 
A, MO, GO: 
↑ Acetate 
↑ Propionate 
↑ Butyrate 
↑ Total SCFA 
[36] 
Ascophyllum 
nodosum 
Sulphated 
polysaccharide extract 
9 
mg/mL 
Yes – non-digestible 
(% digestible 
undisclosed) 
10% (w/v) 
pooled 
inoculum  
(n = 4) 
24 h 
16S rRNA 
NGS 
↑ Bacteroides  
↑ Phascolarctobacterium  
↑ Oscillospira  
↑ Fecalibacterium  
GC-FID 
↑ Acetate 
↑ Propionate 
↑ Butyrate 
↑ Total SCFA 
[100] 
16S rRNA DGGE, 16S rRNA Denaturing Gradient Gel Electrophoresis; 16S rRNA NGS, 16S rRNA Next Generation Sequencing; GC-FID, Gas Chromatography with Flame 
Ionisation Detector; HPLC, High Performance Liquid Chromaography; SCFA, Short Chain Fatty Acid; =, no statistical difference compared to the control; ↑, significant 
increase compared to the control; ↓ significant decrease compared to the control. Microbial and metabolite changes with abbreviations in parenthesis indicate the 
substrate(s) which exerted the effect. If no abbreviations in parenthesis are presented, then all of the seaweed substrates tested exerted the effect. 
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Table 4. continued. 
Seaweed  Substrate Dose 
Use of a 
Simulated in vitro 
Digestion Before 
Fermentation? 
Experimental 
Parameters 
Microbial 
Enumeration 
Microbial Changes 
Metabolomics 
Analysis 
Technique 
Metabolite Changes Reference 
Laminaria 
digitata 
Crude 
polysaccharide 
extract (CE) 
Depolymerised 
crude 
polysaccharide 
extract (DE) 
1% (w/v) 
Yes – non-
digestible (% 
digestible 
undisclosed) 
20% (w/v) 
pooled 
inoculum  
(n = 3) 
48 h 
16S rRNA 
NGS 
↑ Parabacteroides (CE, 
DE) 
↑ Fibrobacter (CE) 
↓ Streptococcus  
↓ Ruminococcus  
↑ Lachnospiraceae UC 
(DE) 
↓ Peptostreptococcaceae 
IS (DE) 
↑ Dialister (CE, DE) 
↑ γ B38UC (CE) 
GC-FID 
↑ Acetate (CE, DE) 
↑ Propionate (CE, 
DE) 
↑ Butyrate (CE, DE) 
↑ Total SCFA (CE, 
DE) 
[101] 
- Laminarin 1% (w/v) 
No – digestibility 
unknown 
10% (w/v) 
pooled 
inoculum  
(n = 5) 
24 h 
qPCR 
↑ Bifidobacterium  
↑ Bacteroides  
HPLC 
↑ Acetate 
↑ Propionate 
↑ Total SCFA 
[79] 
16S rRNA NGS, 16S rRNA Next Generation Sequencing; qPCR, Quantitative PCR; GC-FID, Gas Chromatography with Flame Ionisation Detector; HPLC, High Performance 
Liquid Chromatography; SCFA, Short Chain Fatty Acid; =, no statistical difference compared to the control; ↑, significant increase compared to the control; ↓ significant 
decrease compared to the control. Microbial and metabolite changes with abbreviations in parenthesis indicate the substrate(s) which exerted the effect. If no abbreviations 
in parenthesis are presented, then all of the seaweed substrates tested exerted the effect. 
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2.2. Red Seaweed Polysaccharides 
2.2.1. Galactans (Carrageenan, Agar, and Porphyran) 
Red seaweeds, such as Gelidium spp. and Gracilaria spp., are used in the commercial production 
of agar and carrageenan food additives, including thickening, stabilizing and encapsulation agents 
[53]. A summary of evidence from recent in vitro fermentation experiments using red seaweed-
derived substrates are presented in Table 5. 
Carrageenans are composed of sulphated 1,4-β-D-galactose, 1,3-α-D-galactose, and 3,6-anhydro-
D-galactose [43], and constitutes 30−75% dry weight of red seaweeds [58]. In rats fed 2.5% Chondrus 
crispus, of which carrageenan is a major polysaccharide component, faecal Bifidobacterium breve, and 
acetate, propionate, and butyrate SCFAs were significantly increased alongside a significant decrease 
in the pathogens Clostridium septicum and Streptococcus pneumonia, as compared to the basal diet [15]. 
Furthermore, a 1:1 mixture of polysaccharide extracts from Kappaphycus alvarezii (containing 
carrageenan) and Sargassum polycystum (brown seaweed) has lowered serum lipids in rats [39]. In a 
study by Li et al. [34], β-carrageenase activity in a Bacteroides uniforms 38F6 isolate complex of 
Bacteroides xylanisolvens and Escherichia coli hydrolysed κ-carrageenan oligosaccharides into 4-O-
sulfate-D-galactose, κ-carratriose, κ-carrapentaose, and κ-carraheptaose, which could facilitate cross-
feeding to promote the growth of Bifidobacterium populations.  
Agar is composed of sulphated 1,3-β-D-galactose and 1,4- 3,6-anhydro-α-L-galactose [40] and 
can be fractionated into agarose and agaropectin [8]. Low molecular weight agar of 64.64 kDa has 
demonstrated a bifidogenic effect alongside increased acetate and propionate SCFA concentrations 
after 24 h in vitro fermentation with human stool inoculum [11], while mice fed with 2.5% (w/v) 
neoagarose oligosaccharides for 7 days demonstrated increased caecal and faecal Lactobacillus and 
Bifidobacterium [102]. The utilisation of agaro-oligosaccharides was noted in vitro by Bacteroides 
uniforms L8, isolated from Chinese individuals, which secreted a β-agarase CAZyme to breakdown 
agarooligosaccharides into agarotriose and subsequently facilitated the growth of Bifidobacterium 
infantis and Bifidobacterium adolescentis via the cross feeding of agarotriose [103].  
Porphyran is made up of sulphated 1,3-β-D-galactose, 1,4-α-L-galactose-6-sulfate and 3,6-
anhydro-α-L-galactose [41,104,105]. An in vitro faecal fermentation study indicated that porphyran 
did not significantly increase SCFAs, but stimulated Lactobacillus and Bacteroides populations [79]. 
While pure cultures of Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, 
Bifidobacterium adolescentis, but not Bifidobacterium bifidum, were able to ferment dried Porphyra 
yezoensis (Nori), containing a low protein content (25%), whereas Nori with a high protein content 
(41%) was not fermented [105]. It is likely that carbohydrate content was highest in the low protein 
Nori, thus seasonal- and species-variation and in seaweed macronutrient content should be 
considered a determinant factor for the fermentability of whole seaweeds [106–109]. 
Evidence for the horizontal transfer of genes for porphyranase and agarase CAZymes from the 
marine bacteria, Zobellia galactanivorans, to Bacteroides plebeius of Japanese individuals is indicative of 
diet-driven adaptations of the human gut microbiome [41,44]; however, the North American 
counterparts in this study did not consume seaweeds and the gut microbiota of these individuals did 
not express such CAZymes. This may mean that the fermentation of seaweed polysaccharides, such 
as porphyran and agar, requires exposure to, and acquisition of, specific CAZymes usually present 
in the marine environment [73]. Red seaweed galactans are emerging prebiotic candidates given the 
commercial availability of red seaweed hydrocolloids and the potential gut modulatory effects of 
oligosaccharides obtained from red seaweeds. Nevertheless, further in vivo evidence is needed, given 
the purported pro-inflammatory effects of low molecular weight carrageenan [110–112].  
2.2.2. Xylan 
Xylan, composed of 1,3-1,4-β-D-xylose, is a major constituent of red seaweeds, such as Palmaria 
palmata [46]. A previous in vitro faecal fermentation study of xylan derived from P. palmata, reported 
that xylose was fermented after six h alongside a 58:28:14 ratio of acetate, propionate, and butyrate 
SCFAs (total SCFAs were 107 mM/L) [113]. This study did not ascertain bacterial compositional data, 
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and thus a knowledge gap is presented given that xylans and xylooligosaccharides (XOS) extracted 
from terrestrial plants, such as wheat husks and maize, are mooted as potential prebiotics owing to 
evidence of bifidogenesis, improved plasma lipid profile, and positive modulation of immune 
function markers in healthy adults [114,115]. Given that human gut Bacteroides express a repertoire 
of xylanase and xylosidase CAZymes [116], investigations regarding the capacity of the human gut 
microbiota to catabolise red seaweed xylans and XOS are suggested. 
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Table 5. In vitro fermentation of red seaweeds with human faecal inoculum. 
Seaweed  Substrate Dose 
Use of a Simulated in 
vitro Digestion Before 
Fermentation? 
Experimental 
Parameters 
Microbial 
Enumeration 
Microbial Changes 
Metabolomics 
Analysis 
Technique 
Metabolite 
Changes 
Reference 
Kappaphycus 
alvarezii 
Whole Seaweed 
(WS) 
1% 
(w/v) 
Yes – non-digestible  
(% digestible undisclosed) 
10% (w/v) single 
inoculum 
24 h 
FISH 
↑ Bifidobacterium   
↓ Clostridium coccoides/ 
Eubacterium rectale 
HPLC ↑ Total SCFA [13]  
Osmundea 
pinnatifida 
Osmundea 
pinnatifida  
Viscozyme extract 
(OVE) 
1% 
(w/v) 
Yes – non-digestible  
(% digestible undisclosed) 
10% (w/v) single 
inoculum 
24 h 
FISH 
= Bifidobacterium   
= Lactobacillus   
= Clostridium histolticum 
HPLC ↑Total SCFA [99] 
Gracilaria 
rubra 
Polysaccharide 
extract (PE) 
1% 
(w/v) 
Yes – non-digestible 
(% digestible undisclosed) 
10% (w/v) pooled  
inoculum (n = 4) 
24 h 
16S rRNA  
NGS 
↑ Bacteroides  
↑Prevotella  
↑Phascolarctobacterium  
↓Firmicutes:Bacteroidetes 
GC-FID 
↑ Acetate 
↑ Propionate 
↑ Isobutyrate 
↑ Total SCFA 
[117]  
- Porphyran 
1% 
(w/v) 
No – digestibility 
unknown 
10% (w/v) pooled 
inoculum (n = 5) 
24 h 
qPCR 
↑ Bifidobacterium  
↑ Bacteroides  
HPLC 
= Acetate 
= Propionate 
= Butyrate 
= Total SCFA 
[79]  
FISH, Flourescence in situ Hybridisation; 16S rRNA NGS, 16S rRNA Next Generation Sequencing; qPCR, Quantitative PCR; GC-FID, Gas Chromatography with Flame 
Ionisation Detector; HPLC, High Performance Liquid Chromatography; SCFA, Short Chain Fatty Acid; =, no statistical difference compared to the control; ↑, significant 
increase compared to the control; ↓ significant decrease compared to the control. Microbial and metabolite changes with abbreviations in parenthesis indicate the 
substrate(s) which exerted the effect. If no abbreviations in parenthesis are presented, then all of the seaweed substrates tested exerted the effect. 
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2.3. Green Seaweed Polysaccharides 
2.3.1. Ulvan 
Ulvans are water-soluble cell wall polysaccharides that account for 8–29% dry weight of green 
seaweeds, and are composed of sulphated 1,3-α-L-rhamnose, 1,4-β-D-glucuronic acid, and 1,4-β-D-
xyloglucan [51]. Previous reports indicate that Ulva lactuca and ulvan polysaccharides are poorly 
fermented by the human gut microbiota [8,95,118], while an in vitro fermentation study of 
Enteromorpha spp. With a human faecal inoculum reported no difference in Enterococcus, Lactobacillus, 
and Bifidobacterium populations compared to the control; only an increase in Enterobacter after 24 h 
and 48 h of fermentation (Table 6) [12]. In contrast, a recent in vitro faecal fermentation study 
indicated that Ulvan stimulated the growth of Bifidobacterium and Lactobacillus populations and 
promoted the production of lactate and acetate [79]. Further, a murine study showed that 
Enteromorpha (EP) and Enteromorpha polysaccharides (PEP) ameliorated inflammation associated 
with Loperamide-induced constipation in mice [119], where alpha diversity, Firmicutes, and 
Actinobacteria were increased in the faecal microbiota of seaweed-supplemented mice compared to 
the constipated control. Bacteroidetes and Proteobacteria were decreased, while Bacteroidales family 
S24-7 and Prevotellaceae were increased in EP and PEP, respectively. Current evidence for the 
fermentation of green seaweeds and their polysaccharides is limited and fermentation may require 
specific α-L-rhamnosidase activity by gut commensals [50]. More experimental evidence is needed to 
understand the impact of ulvans and ulvan-oligosaccharides in the human and animal diet.  
2.4. Future Prospective–Obtaining Oligosaccharides 
Enzyme technologies are reported to increase the extraction yield and reduce the molecular 
weight of bioactive components obtained from seaweeds, with examples of enhanced prebiotic 
activity when commercially available cellulases or seaweed-specific enzymes were used to hydrolyse 
polysaccharides [99,120]. Despite limited commercial availability of seaweed-specific enzymes, an 
avenue for functional oligosaccharide production is presented if efforts to develop commercially 
viable saccharolytic enzymes from microorganisms (primarily marine). Examples of such glycoside 
hydrolases include fucoidanase from Sphingomonas paucimobilis PF-1 [121]; ulvan lyase from 
Alteromonas spp. [122] and the family Flavobacteriaceae [123]; β-agarase from Cellulophaga omnivescoria 
W5C [124] and Cellvibrio PR1 [125]; alginate lyase from Flammeovirga [126], and Paenibacillus [70]; and 
laminarinase from Clostridiium thermocellum [127]. Factors which influence the stability and efficacy 
of such hydrolytic enzymes may include metal ion interaction, or thermostability at the high 
temperatures needed to prevent gelling of polysaccharides. Recent insight into the production of 
agarose oligosaccharides and neoagarose oligosaccharides from agar exemplify this [128]. 
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Table 6. In vitro fermentation of green seaweeds with human faecal inoculum. 
Seaweed  Substrate Dose 
Use of a Simulated 
in vitro Digestion 
Before 
Fermentation? 
Experimental 
Parameters 
Microbial 
Enumeration  
Microbial 
Changes 
Metabolomics 
Analysis 
Technique 
Metabolite 
Changes 
Reference 
Enteromorpha 
prolifera 
Polysaccharide 
extract (PE) 
0.2 g in 9.5 mL 
0.8 g in 9.5mL 
Yes-non-digestible 
(% digestible 
undisclosed) 
10.5% (w/v) 
pooled 
inoculum (n = 3) 
12, 24, and 48 h 
Microbial 
culture 
↑ Enterobacter (0.2 
PE and 0.8 PE at 
24 h and 48 h) 
= Enterococcus  
= Lactobacillus  
= Bifidobacterium  
GC-FID 
= Acetate 
= Butyrate 
= Lactate 
[12] 
- Ulvan 1% (w/v) 
No-digestibility 
unknown 
10% (w/v) 
pooled 
inoculum (n = 5) 
24 h 
qPCR 
↑ Bifidobacterium  
↑ Lactobacillus  
HPLC 
↑ Acetate 
↑ Lactate 
[79] 
qPCR, Quantitative PCR; GC-FID, Gas Chromatography with Flame Ionisation Detector; HPLC, High Performance Liquid Chromatography; =, no statistical difference 
compared to the control; ↑, significant increase compared to the control; ↓ significant decrease compared to the control. Microbial and metabolite changes with abbreviations 
in parenthesis indicate the substrate(s) which exerted the effect. If no abbreviations in parenthesis are presented, then all of the seaweed substrates tested exerted the effect. 
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Table 7. Impact of seaweeds on the rodent gut microbiota. 
Animal Substrate Dose Duration Biological Sample Microbial Changes Metabolite Changes Reference 
30 Male Sprague-
Dawley Rats 
Chondrus crispus  
Whole Seaweed (WS) 
0.5% (w/w)  
2.5% (w/w)  
21 days Faeces 
↑Bifidobacterium ↑ Legionella ↑ Sutterella  
↑ Blautia ↑ Holdemania  
↑ Shewanella ↑ Agarivorans  
↓ Streptococcus  
↑ Bifidobacterium breve (2.5% WS) 
↑ Acetate  
↑ Propionate (2.5% WS) 
↑ Butyrate  
↑ Total SCFA 
[15] 
24 Male Sprague-
Dawley Rats 
Ecklonia radiata Whole 
Seaweed (WS) 
Ecklonia radiata 
Polysaccharide 
Fraction (PF) 
5% (w/w) WS 
5% (w/w) PF 
7 days Caecum 
↑ F. prausnitzii ↑ E. coli (PF) 
↓ Enterococcus (WS) 
↓ Lactobacillus ↓ Bifidobacterium  
↓ Firmicutes:Bacteroidetes  
↑ Acetate  
↑ Propionate  
↑ Butyrate (PF) 
↓ Valerate 
↓ Hexanoate 
↑ Total SCFA  
↓ i-Butyrate  
↓ i-Valerate  
↓ phenol  
↓ p-cresol 
[129]  
18 Male Wistar 
Rats 
Alginate (A) 
Laminarin (L) 
Fucoidan (F) 
2% (w/w) 14 days Caecum 
↑ Bacteroides (Bacteroides capillosus) 
Presence of Enterorhabdus (A) 
↑ Proteobacteria. Presence of Lachnospiracea, 
Parabacteroides (Parabacteroides distasonis) and 
Parasutterella (L) 
Not fermented (F) 
↑ Propionate (L) 
↑ Total SCFA (A, L) 
[97] 
SCFA, Short Chain Fatty Acid; =, no statistical difference compared to the control; ↑, significant increase compared to the control; ↓ significant decrease compared to the 
control. Microbial and metabolite changes with abbreviations in parenthesis indicate the substrate(s) which exerted the effect. If no abbreviations in parenthesis are 
presented, then all of the seaweed substrates tested exerted the effect. 
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Table 7. continued. 
Animal Substrate Dose Duration Biological Sample Microbial Changes Metabolite Changes Reference 
16 Male 
C57 BL/6 Mice 
Saccorhiza polyschides 
extract (BAE) 
High fat diet + 
5% (w/w) BAE 
8 months Faeces ↓ Faecal bile salt hydrolase activity ↓ Secondary bile acids [54] 
18 Male Wistar 
Rats 
Alginate (A) 
Laminarin (L) 
2% (w/w)  14 days Caecum 
↑ Lactobacillus ↑ Porphyromonas 
↑Coprobacillus  
↑ Oscillibacter valencigenes  
↓ Parabacteroides (L) 
↑ Catabacter honkongensis  
↑ Stomatobaculum longum 
↓ Adlercreuzia (A) 
↓ Helicobacter (A, L) 
↑ Lactic acid (L) 
= Acetate 
= Propionate  
= Butyrate  
= Total SCFA  
↓ Indole 
[130] 
18 Male 
C57BL/6 mice 
Ascophyllum nodosum 
Fucoidan (FuA) 
Laminaria 
japonica Fucoidan (FuL) 
100 mg/kg/day 6 weeks Caecum 
↑ Lactobacillus ↑Anaeroplasma  
↑ Thalassospira (FuA) 
↑ Ruminococcaceae ↓ Alistipes  
↓ Clostridiales 
↓ Akkermansia (FuL) 
↓ Candidatus ↓ Arthromitus  
↓ Peptococcus  
↓ Lachnospiraceae Incertae Sedis 
(FuA, FuL)  
- [96] 
SCFA, Short Chain Fatty Acid; =, no statistical difference compared to the control; ↑, significant increase compared to the control; ↓ significant decrease compared to the 
control. Microbial and metabolite changes with abbreviations in parenthesis indicate the substrate(s) which exerted the effect. If no abbreviations in parenthesis are 
presented, then all of the seaweed substrates tested exerted the effect. 
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Table 7. continued. 
Animal Substrate Dose Duration 
Biologica
l Sample 
Microbial Changes Metabolite Changes Reference 
15 Male 
Wistar rats 
Ascophyllum nodosum 
seaweed crude 
polysaccharide (SCP) 
SCP Lactobacillus plantarum 
hydrolysate (SCPH Lp) 
SCP Enterococcus fecalis 
hydrolysate (SCPH Ef) 
Alginate (A) 
Hydrolysed Alginate (HA) 
0.2 g 
per 180 
–200 g 
rat 
weight 
4 days Faeces - 
↑ Acetate (HA > A > SCPH Lp > SCPH Ef) 
↑ Propionate (HA = A = SCPH Lp = SCPH Ef) 
↑ Butyrate (HA = A = SCPH Lp = SCPH Ef) 
(relative to day zero) 
[131] 
32 Female 
Kunming 
mice 
Enteromorpha prolifera (EP) 
Enteromorpha polysaccharide 
extract (PEP) 
1:5 
(w/w) 
7 days Faeces 
↑Alpha diversity (EP) 
↑ Bacteroidales S24-7 (EP) 
↑ Prevotellaceae (PEP) 
↑ Firmicutes ↑Actinobacteria 
(EP, PEP) 
↓ Bacteroidetes ↓ Proteobacteria 
(EP, PEP) 
- [119] 
=, no statistical difference compared to the control; ↑, significant increase compared to the control; ↓ significant decrease compared to the control. Microbial and metabolite 
changes with abbreviations in parenthesis indicate the substrate(s) which exerted the effect. If no abbreviations in parenthesis are presented, then all of the seaweed 
substrates tested exerted the effect. 
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3. Polyphenols 
Seaweeds are rich in polyphenols, such as catechins, flavonols, and phlorotannins. Red and 
green seaweeds are a source of bromophenols, phenolic acids, and flavonoids [132], while 
phlorotannins are the most abundant polyphenol in brown seaweeds. Most research to date concerns 
the bioactivity of phlorotannins, a class of polyphenol unique to brown algae comprised of 
phloroglucinol monomers and categorised as eckols, fucols, fuhalols, ishofuhalols, phloroethols, or 
fucophloroethols [132]. The purported bioactivities of seaweed polyphenols are associated with the 
mitigation of risk factors pertained to type 2 diabetes and cardiovascular disease, including 
hyperglycemia, hyperlipidemia, inflammation and oxidative stress [133–137], and also anti-microbial 
activity [138]. Owing to heterogeneity in both molecular weight and the level of isomerisation, 
characterisation of polyphenols is difficult [139–141], and a paucity of information exists regarding 
the endogenous digestion and microbial catabolism of seaweed polyphenols, with a scarce 
mechanistic understanding of how they may exert health benefits via the gut microbiota.  
Most polyphenols of plant origin must undergo intestinal biotransformation by endogenous 
enzymes and the gut microbiota prior to absorption across enterocytes. These enzymatic 
transformations include the elimination of glycosidic bonds, for example, flavonoids are converted 
to glycones (sugars) and aglycones (non-sugars–polyphenols) by endogenous β-glucosidases in the 
small intestine [142]. The transport of aglycones to the liver via the portal vein results in phase II 
biotransformation (coupling reactions, chiefly hepatic conjugation to O-glucuronides and O-sulfates) 
to facilitate urinary and biliary elimination. Phase II metabolites are absorbed into the systemic 
circulation, or excreted in bile and re-enter the duodenum (hepatic recycling), where subsequent 
glucuronidase, glycosidase, or sulphatase-mediated deconjugation by the colonic microbiota may 
favour aglycone reabsorption [143]. 
Approximately 90–95% of dietary polyphenols reach the colon intact [144], where 
biotransformation and metabolism by the gut microbiota occurs via hydrolysis, reduction, 
decarboxylation, demethylation, dehydroxylation, isomerisation, and fission [145], to produce low-
molecular weight compounds with less chemical heterogeneity than the polyphenol parent 
compound [142]. It is suggested that a complex network of gut microbial species is necessary for full 
biotransformation of polyphenols, whereas simple reactions, such as deglycosylation, can be 
achieved by individual gut strains. Furthermore, the bioactivities associated with dietary polyphenol 
intake may be dependent on the catabolic capacity and composition of the gut microbiota, owing to 
the biological activity of metabolites rather than the parent polyphenol compound present in food 
[146,147], while a synergistic effect between prebiotic polyphenols and probiotic bacteria may occur 
[6]. 
The identification of bacteria which possess the metabolic capabilities to utilise polyphenols was 
previously identified in Eubacterium oxidoreducens, which could catabolise gallate, pyrogallol, 
phloroglucinol and quercetin [148]. Quercetin biotransformation by Eubacterium ramulus has also 
been identified [149], and multiple human gut microbes which possess phenolic enzymes capable of 
breaking down glycosides, glucuronides, sulphates, esters, and lactones was summarised by Selma 
et al. [145]. Such microorganisms included E. coli with β-glucuronidase activity; Eubacterium, 
Bacteroides, and Clostridium with β-glucosidase activity; Lactobacillus, Eubacterium, Clostridium , 
Butyrbacterium, Streptococcus, and Methylotrophicum with demethylase activity; and E. coli, 
Bifidobacterium, Lactobacillus, Bacteroides, Streptococcus , Ruminococcus, and Enterococcus with esterase 
activity. There is also evidence for α-L-Rhamnosidase mediated hydrolysis of rutinose, present on 
glycosylated polyphenols (rhamnoglycosides), to produce aglycones, by species, such as Bacteroides 
thetaiotaomicron [50], Bifidobacterium dentium [150], Bifidobacterium catenulatum [151], Bifidobacterium 
pseudocatenulatum [151], and Lactobacillus plantarum [152]. 
Current knowledge regarding the fate of seaweed polyphenols in the human gastrointestinal 
tract is scarce; however, it is understood that the limited absorption of Ascophyllum nodosum 
polyphenols from small intestinal enterocytes to the portal vein may facilitate the conjugation of 
polyphenols to methylated, glucuronidated, or sulphated forms rather than hydrolysis to aglycones 
[153,154]. Subsequently, unabsorbed conjugated polyphenols are available for biotransformation by 
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the colonic microbiota, then potentially absorbed across the colonocytes. Indeed, Corona et al. [154], 
observed a reduction of total polyphenol contents of an Ascophyllum nodosum polyphenol extract, 
high molecular weight fraction (>10 kDa), and low molecular weight fraction (1–10 kDa) following in 
vitro digestion and batch culture fermentation; although anti-genotoxic activity against H2O2 induced 
DNA damage of HT-29 cells was increased (to a greater extent by the high molecular weight fraction). 
This study did not assess the microbiota composition, however, elsewhere, an in vitro fermentation 
of an Ecklonia radiata phlorotannin extract significantly increased Bacteroidetes, Clostridium coccoides, 
E. coli, and Fecalibacterium prausnitzii, but decreased Bifidobacterium and Lactobacillus populations after 
24 h fermentation [56]. More in vitro digestion studies would be useful to understand the stability of 
seaweed polyphenols as extracts or within the seaweed matrix [155,156]. These studies may be 
complemented by studies which use ileostomy patient cohorts to determine structural changes to 
seaweed polyphenols following upper GI digestion in vivo to indicate polyphenol bioaccessibility in 
the colon [157].  
A recent review highlighted the potential for dietary polyphenols to modulate the gut 
microbiota by increasing Bifidobacterium, Lactobacillus, Bacteroides, Enterococcus, Akkermansia 
muciniphila, and Fecalibacterium prausnitzii populations [158]. This review did not include any studies 
which assessed modulation of the gut microbiota by seaweed polyphenols and, therefore, a research 
opportunity is presented. Inter-individual variation of gut microbiota composition and function is 
the key determinant for gut microbiota-mediated biotransformation of phenolic compounds to 
bioactive metabolites [159,160]. Therefore, identification of bacterial species or strains with the ability 
to catabolise seaweed polyphenols and their respective catabolic machinery is needed to understand 
if seaweed polyphenols could be prebiotic [161,162]. Moreover, considering that gut microbiota-
derived secondary metabolites reach a peak plasma concentration much later than the original 
aglycone or hepatic conjugates, controlled nutrikinetic studies could elude how dietary polyphenols 
from seaweeds interact with host-microbiota metabolism [163,164]. Identification of faecal, urinary, 
serum, or tissue biomarkers via untargeted and targeted metabolomics approaches, and the use of 
stable isotope studies, may also indicate variation in synthesis, bioavailability, metabolism, and 
excretion of polyphenols and associated metabolites. While integration of dose response studies 
alongside metagenomics and metabolomics analyses, akin to those conducted for berry and wine 
polyphenols, could elude how much seaweed polyphenol is required to have an impact, if any, on 
gut microbial composition, metabolic function, and host health [165,166]. 
4. Other Seaweed Phytochemicals 
4.1. Carotenoids 
Carotenoids are lipid soluble compounds which function within the photosynthetic machinery 
of seaweeds to produce pigments. Fucoxanthin is the predominant carotenoid in brown seaweeds 
[167], while lutein, β-carotene, astaxanthin, echinenone, violaxanthin, neoxanthin, and zeaxanthin are 
found in red and green seaweeds. Carotenoids are used as food colouring additives, while the 
application of fucoxanthin as functional food ingredients is suggested, owing to putative anti-
oxidant, anti-inflammatory, anti-cancer, anti-obesity, and anti-diabetic bioactivities [168–173]. 
While some carotenoids are absorbed by enterocytes and converted into vitamin A and retinoid 
derivatives by endogenous beta‐carotene oxygenase 1 (BCO1) and beta‐carotene dioxygenase 2 
(BCO2) enzymes [174,175], the bioavailability of carotenoids in the blood is reported as 10−40% [176], 
which has led to suggestions that carotenoids could be fermented by the gut microbiota [174,177]. 
The only evidence to date has demonstrated that male C57BL/6J mice supplemented with 0.04% (w/w) 
astaxanthin during an eight-week pilot study had increased abundance of caecal Bifidobacterium [178], 
whereas Proteobacteria and Bacteroides were significantly increased in the caecum of BCO2 knockout 
mice; however, analysis of health biomarkers was not reported. Given the differences in microbiota 
composition between wild type and BCO2 knockout mice in this study, there is scope to investigate 
how carotenoids and their endogenous derivatives interact with the gut microbiota. Looking ahead, 
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the use of in vitro models of gastrointestinal digestion and colonic fermentation would be useful to 
assess whether there is a direct substrate to microbiota effect or a host–microbe effect [179]. 
4.2. Polyunsaturated Fatty Acids (PUFAs) 
The lipid content of seaweed ranges from 1–5% dry weight, which includes n-3 PUFAs, such as 
eicosapentanoic acid (EPA) and docosahexaenoic acid (DHA) [180,181]. The n-3 PUFA are associated 
with the anti-inflammatory activity to reduce cardiovascular disease risk and may also exert 
beneficial effects on brain function and behaviour, as mediated by the microbiota-gut-brain axis [182]. 
Dietary EPA and DHA intake are reported to improve microbial diversity, reduce the 
Firmicutes/Bacteroidetes ratio, reduce LPS-producing bacteria, and increase populations of 
Bifidobacterium, Lachnospiraceae, and lipopolysaccharide (LPS)-suppressing bacteria in both humans 
and animal models [182–184]. Although the evidence to date has focused on fish-derived n-3 PUFA, 
great scope exists to evaluate the prebiotic effect of n-3 PUFA obtained from seaweeds. 
5. Fermented foods 
Fermented foods are understood to have improved nutritional and functional properties owing 
to bioactive or bioavailable components [185]. Seaweeds (mainly kelp) are a common vegetable 
ingredient in the fermented food, Kimchi. The microbial content of kimchi provides a source of 
probiotics, nutrients, and bioactive metabolites, which are reported to have anti-microbial, anti-
oxidant, and anti-obesogenic activities [186–188]. One randomised controlled trial (RCT) observed 
that consumption of a seaweed Kimchi made from L. japonica for four weeks promoted the growth 
and survival of gut microbial lactic acid bacteria in humans [189], whilst another RCT concluded that 
consumption of 1.5 g/day fermented L. japonica containing 5.56% γ-aminobutyric acid (GABA) 
(Lactobacillus brevis BJ2 culture) was associated with a reduction in oxidative stress in healthy adults 
over four weeks, indicated by decreased serum γ-glutamyltransferse (GGT) and malondialdehyde, 
and increased antioxidant activity of superoxide dismutase and catalase compared to the placebo 
[190]. The latter study indicates that foods containing fermented brown seaweeds, such as L. japonica, 
may offer a novel source of GABA enriched ingredients, which are associated with hypotensive and 
anti-inflammatory effects [188]. Anti-oxidant, anti-diabetic, and anti-hypertensive efficacies are also 
reported for Korean rice wine fermented with L. japonica [191], while Sargassum fermented with a 
starter culture of Enterococcus faecium was reported to contain higher soluble polyphenol and 
mannuronic acid-rich alginate contents [192], which may increase the provision of microbiota 
accessible components for colonic fermentation.  
Reports of the functional properties of fermented foods containing red seaweeds are scarce; 
however, examples of red seaweed fermented foods include a fermented Porphyra yezoensis seaweed 
sauce, which used the marine halophilic lactic acid bacteria, Tetragenococcus halophilus, as a starter 
culture [193]; a Gracilaria domingensis aqueous extract applied as a texture modifier in fermented milks 
as a non-animal alternative to gelatin [194]; and carrageenan as a salt replacer in the production of 
fat-free cheese [195].  
Given the availability of red, brown, and green seaweeds both commercially and locally [196], 
the production of seaweed-containing fermented foods could be a cost-effective alternative to 
bioactive component extraction. Nevertheless, an understanding of how live bacteria and bacterial 
metabolites present in fermented foods contribute towards health is required [185]. 
6. Seaweeds and Animal Health 
Seaweeds also have a historical use as animal feed ingredients [197]. The capacity for seaweeds 
to modulate the gut microbiota of monogastrics, such as pigs and hens, is presented in Table 8 and 
Table 9, respectively, which complements the recent evidence for the application of seaweed 
bioactives in monogastric animal feed [198]. Table 8 shows limited evidence that the β-glucan, 
laminarin, may increase Lactobacillus populations but not Bifidobacterium populations. While there is 
scarce evidence for the selective stimulation of health-associated bacteria in pigs by the sulphated 
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fucose, fucoidan. Only one recent study has evaluated the effect of dietary alginate on the porcine 
microbiota, where the genera Ruminococcus, Roseburia and Lachnospira, and an unclassified bacterium 
of the F16 family were increased, alongside a significant decrease in the genus Blautia, the family 
Clostridiaceae, and an unclassified bacterium of RF39 family [199]. In Table 9, recent evidence indicates 
that hens fed Chondrus crispus and Sarcodiotheca gaudichaudii red seaweeds may increase ceacal SCFA 
concentrations and modulate populations of Bifidobacterium longum, Lactobacillus acidophilus, 
Streptococcus salivarius, and Clostridium perfringens [200,201]; however, a bidirectional change in 
microbial composition was dose dependent and has only been assessed in two studies to date. Given 
the use of pigs as an animal model of humans [202], data from in vivo monogastric studies which are 
designed to evaluate the prebiotic potential of dietary seaweeds and seaweed-derived components 
could provide insight into the potential for human applications. 
Table 10 and Table 11 summarise recent studies which have examined the impact of seaweed 
diets on the ruminant microbiota of cows and sheep, respectively, with the potential application of 
reducing methane production. Despite demonstrating decreased methane production, the cow 
rumen in vitro fermentation studies presented in Table 10 did not assess microbiota compositional 
changes, thus a knowledge gap is presented to understand which bacteria (if any), are increased or 
decreased, and are associated with a reduction in methane production. Table 11 shows that 
methanogenic bacteria and methane production were significantly decreased compared to the basal 
grass substrate control following the in vitro fermentation of sheep rumen with the red seaweed 
Asparagopsis taxiformis [203]. While sheep given an ad libitum diet of Ascophyllum nodosum brown 
seaweed (1%, 3%, or 5% w/w) for 21 days demonstrated a dose-dependent decrease in propionate and 
butyrate SCFAs and a dose-dependent increase in acetate [204], while several bacteria were 
significantly decreased, including Prevotella copri, Roseburia, and Coprococcus, while Blautia producta 
and the family Veillonellaceae were significantly increased compared to the basal diet. Moreover, the 
specific case of seaweed-fed North Ronaldsay sheep highlights how isolated organisms of the 
ruminant microbiome, such as Prevotella, Clostridium butyricum, Butyrivibrio fibrisolvens, and 
Spirochaetes have adapted to hydrolyse alginate laminarin, and fucoidan [205,206]. However, there 
is a paucity of evidence to implicate any health benefits attributed to a seaweed diet in these animals. 
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Table 8. Impact of seaweeds on the porcine gut microbiota. 
Animal Seaweed Component Dose Duration Biological Sample Microbial Changes Metabolite Changes Reference 
20 pregnant 
gilts and 48 
piglets 
Laminarin/Fucoidan 
Extract 
10 g/day  
Gestation (day 83) 
to weaning (day 28) 
Faeces (Sow) 
Colonic digesta (Piglet) 
Sows (parturition): ↓ Enterobacteriaceae 
 = Lactobacilli 
Piglets (birth, 48h after birth, weaning): 
= Enterobacteriaceae = Lactobacilli 
- [207] 
200 pigs 
Ecklonia cava Whole 
Seaweed 
0.05% (w/w) 
0.1% (w/w) 
0.15% (w/w)  
28 days Caecum 
↑ Lactobacillus  
↓ E. coli 
= Total Anaerobes 
- [208] 
24 pigs 
Laminarin/Fucoidan 
Extract (SD) 
Laminarin/Fucoidan Wet 
Seaweed (WS) 
5.37 Kg/tonne SD 
26.3 Kg/tonne WS 
21 days 
Ileum  
Caecum  
Colon 
= Bifidobacteria  
= Lactobacillus 
= Enterobacterium (SD, WS) 
↑ Lactobacillus agilis (colon) 
- [209] 
48 pigs Laminarin Extract 300 ppm  32 days Faeces 
↑ Lactobacillus  
= Bifidobacteria 
= Acetate 
↓ Propionate  
= Butyrate 
= Valerate  
= i-Butyrate 
= i-Valerate 
[210] 
48 pigs β-glucan 
250 g/tonne 
150 g/tonne 
29 days 
Ileum 
Caecum 
Proximal Colon Distal 
Colon 
= Lactobacilli  
= Bifidobacteria. 
↑ Lactobacillus diversity 
- [211]  
=, no statistical difference compared to the control; ↑, significant increase compared to the control; ↓ significant decrease compared to the control. Microbial and metabolite 
changes with abbreviations in parenthesis indicate the substrate(s) which exerted the effect. If no abbreviations in parenthesis are presented, then all of the seaweed 
substrates tested exerted the effect. 
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Table 8. continued. 
Animal 
Seaweed 
Component 
Dose Duration 
Biological 
Sample 
Microbial Changes Metabolite Changes Reference 
168 pigs 
Laminarin (L)  
Fucoidan (F) 
240 mg/kg F 
150 mg/kg L 
300 mg/kg L 
150 mg/kg L and 240 
mg/kg F 
300 mg/kg L and 240 
mg/kg F 
35 days Faeces 
= E. coli  
= Bifidobacteria  
↑ Lactobacilli 
= Acetate 
= Propionate 
= Butyrate 
= Valerate 
= i-Butyrate 
= i-Valerate 
= Total SCFA 
[212] 
9 pigs Alginate 5.14% (w/w)  84 days Faeces 
= Diversity 
↑ Unclassified F16 family  
↓ Clostridiaceae  
↓ Unclassified RF39 (Mollicutes) 
↑ Ruminococcus  
↑ Roseburia  
↑ unclassified F16 genus (TM7)  
↑ Lachnospira  
↓ Blautia  
- [199]  
=, no statistical difference compared to the control; ↑, significant increase compared to the control; ↓ significant decrease compared to the control. Microbial and metabolite 
changes with abbreviations in parenthesis indicate the substrate(s) which exerted the effect. If no abbreviations in parenthesis are presented, then all of the seaweed 
substrates tested exerted the effect. 
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Table 9. Impact of seaweeds on the hen gut microbiota. 
Animal Seaweed Component Dose Duration 
Biological 
Sample 
Microbial Changes Metabolite Changes Reference 
160 
laying 
hens 
Chondrus crispus  
Whole Seaweed (CC) 
Sarcodiotheca 
gaudichaudii  
Whole Seaweed (SG) 
0.5% (w/w)  
1% (w/w)  
2% (w/w)  
30 days 
Ileum 
Caecal 
digesta 
↑ Bifidobacterium longum (CC2, SG1, SG2) 
↑ Streptococcus salivarius (CC1, CC2, SG2) 
↓ Clostridium perfringens (CC1, CC2, SG1, 
SG2) 
↓ Lactobacillus acidophilus (CC1, CC2) 
↑ Acetate (CC1, SG1) 
↑ Propionate (CC2) 
↑ Butyrate (SC2) 
[200] 
96 laying 
hens 
Chondrus crispus  
Whole Seaweed (CC) 
Sarcodiotheca 
gaudichaudii  
Whole Seaweed (SG) 
Control diet + 2% 
(w/w) seaweed 
Control diet + 4% 
(w/w) seaweed 
28 days Caecum 
↑ Lactobacillus acidophilus (CC4) 
↓ Bifidobacterium longum (SG2, SG4, CC4) 
↓ Streptococcus salivarius (SG2, SG4, CC2, 
CC4) 
↑ Bacteroidetes (SG4, CC2, CC4) 
↑ Propionate (CC4) [201] 
=, no statistical difference compared to the control; ↑, significant increase compared to the control; ↓ significant decrease compared to the control. Microbial and metabolite 
changes with abbreviations in parenthesis indicate the substrate(s) which exerted the effect. If no abbreviations in parenthesis are presented, then all of the seaweed 
substrates tested exerted the effect. 
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Table 10. In vitro fermentation of seaweeds with cow rumen inoculum. 
Seaweed Substrate 
Experimental 
Parameters 
Dose 
(w/v) 
Microbial 
Enumeration 
Microbial 
Changes 
Metabolomics Analysis 
Technique 
Metabolite Changes Reference 
Ascophyllum nodosum (AN)  
Laminaria digitata (LD)  
Whole 
Seaweed 
50% pooled inoculum  
(n = 4)  
24 h 
0.5g/L 
1g/L  
2g/L 
-  - GC-FID 
↑Propionate  
↑Butyrate (LD) 
↓ BCFA 
↓Methane 
[213] 
Asparagopsis taxiformis 
Whole 
Seaweed 
20% pooled inoculum  
(n = 4) 
72 h 
0.5% 
1% 
2% 
5% 
10% 
-  - GC-FID 
↓ Total gas production 
↓ Methane  
↓ Acetate  
↑ Propionate 
↑ Butyrate (2%, 10%) 
↓ Total SCFA (5%, 10%) 
[214] 
Ulva sp. 
Laminaria ochroleuca 
Saccharina latissima 
Gigartina sp. 
Gracilaria vermiculophylla 
Whole 
Seaweed 
20% pooled inoculum  
(n = 2) 
24 h 
25% - - GC-FID ↓ Methane [215] 
Brown seaweed by-products 
(BSB) 
- 
50% (v/v) 
single inoculum 
0, 3, 6, 9, 12, and 24 h 
2% 
4% 
- - GC-FID 
↓ Ammonia (3, 9, 12 and 
24h) 
↓ Total SCFA (24h) 
[216] 
GC-FID, Gas Chromatography; =, no statistical difference compared to the control; ↑, significant increase compared to the control; ↓ significant decrease compared to the 
control. Microbial and metabolite changes with abbreviations in parenthesis indicate the substrate(s) which exerted the effect. If no abbreviations in parenthesis are 
presented, then all of the seaweed substrates tested exerted the effect. 
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Table 11. Impact of seaweeds on the sheep rumen microbiota. 
Seaweed Dose Experimental Parameters 
Microbial 
Enumeration 
Microbial Changes 
Metabolomics 
Analysis Technique 
Metabolite Changes Reference 
Asparagopsis 
taxiformis 
Whole Seaweed 
2% 
in vitro batch culture 
fermentation 
20% (v/v) pooled sheep rumen 
fluid inoculum (n = 4) 
48 and 72 h 
16S rRNA NGS 
qPCR 
↓Methanogens 
↓Bacteroidetes/Firmicutes ratio 
↓ mcrA gene expression 
GC-MS 
↓ Total Gas 
↓ Methane 
↑ Hydrogen 
[203] 
Ascophyllum 
nodosum 
Whole Seaweed 
1% 
3% 
5% 
Rams (n = 8) 
21 days ad libitum 
16S rRNA NGS 
↓ undefined TM7-1 
↓undefined Coriobacteriaceae 
↓Roseburia 
↓Coprococcus  
↓Prevotella copri 
↑Blautia producta 
↑ Entodinium species 1 
↑Veillonellaceae 
GC-FID 
Dose dependent: 
↑ Acetate 
↓ Propionate 
↓ Butyrate 
PICRUSt: 
↑Butanoate metabolism 
↑ Fatty acid metabolism 
↓Glycerophospholipid 
metabolism 
[204] 
16S rRNA NGS, 16S rRNA Next Generation Sequencing; qPCR, Quantitative PCR; GC-FID, Gas Chromatography; =, no statistical difference compared to the control; ↑, 
significant increase compared to the control; ↓ significant decrease compared to the control. Microbial and metabolite changes with abbreviations in parenthesis indicate 
the substrate(s) which exerted the effect. If no abbreviations in parenthesis are presented, then all of the seaweed substrates tested exerted the effect. 
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7. Conclusions 
Current evidence regarding the prebiotic effects of seaweeds is dominated by complex 
polysaccharide components. This is because prebiotic research was previously focused on 
saccharolytic fermentation by the gut microbiota. Accumulating evidence from in vitro and in vivo 
animal studies provides encouraging data regarding the utilisation of red seaweed galactans and 
brown seaweed glycans, such as alginates and laminarins, with minor evidence for fucoidan and the 
green seaweed polysaccharide, ulvan.  
Given that the most recent definition of prebiotic places non-complex polysaccharide 
components in vogue, an opportunity is presented to explore how other seaweed phytochemicals, 
including polyphenols, carotenoids, and PUFAs, are metabolised by host microbial populations to 
benefit host health. Future investigations should consider the use of in vitro screening studies and in 
vivo animal studies to identify putative prebiotic compounds from seaweeds via the identification of 
host organisms which utilise seaweed components and the bioactive metabolites produced (via 
untargeted metabolomics). Furthermore, controlled human intervention studies with health-related 
end points to elucidate prebiotic efficacy are required. 
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